Purification of cell culture derived alpha1 protease inhibitor

ABSTRACT

Described herein are methods for purifying recombinant, cell culture derived alpha 1 -protease inhibitor and removing a colored species that co-purifies with the recA1PI protein. Also described are methods for reducing the iron in cell culture derived alpha 1 -protease inhibitor.

This application is a complete application of U.S. Provisional PatentAppln. Ser. No. 61/675,560, filed Jul. 25, 2012, incorporated herein byreference.

TECHNICAL FIELD

Described herein are methods for purifying human recombinant cellculture derived alpha₁-protease inhibitor (recA1PI) and removing acolored species that co-purifies with the recA1PI protein.

BACKGROUND

Alpha₁-proteinase inhibitor (abbreviated herein as A1PI; also known asalpha-1 protease inhibitor, alpha-1, PI, A₁PI, α-1 PI, α₁PI, alpha-1trypsin inhibitor, alpha₁ antitrypsin, alpha-1 antitrypsin, alpha1AT,A1A, and A1AT, AAT, inter alia), is the major serine protease inhibitor(serpin) in humans. A1PI is expressed as a 418 amino acid protein withresidues 1-24 being a signal peptide. The mature protein, consisting ofresidues 25-418, is a single chain glycoprotein having a molecularweight of about 51 kD. See FIG. 1. While A1PI does not contain anydisulfide bonds, the protein is highly structured, with 80% of the aminoacids residing in eight well-defined α-helices and three large β-sheets.Three asparagine-linked carbohydrates are found on Asn 70, Asn 107, andAsn 271 (numbered as in the full-length protein). This gives rise tomultiple A1PI isoforms, having isoelectric points in the range of 4.0 to5.0. The glycan monosaccharides include N-acetylglucosamine, mannose,galactose, fucose, and sialic acid.

Normal plasma concentrations of A1PI range from 1.3 to 3.5 mg/mL. A1PIfunctions by protecting cells from proteases involved in clotting andinflammation. A1PI inhibits trypsin, chymotrypsin, various forms ofelastases, skin collagenase, renin, urokinase, and proteases ofpolymorphonuclear lymphocytes, among others. A1PI serves as apseudo-substrate for these proteases, which attack the reactive centerloop of the A1PI molecule (residues Gly 368-Lys 392) by cleaving thebond between residues Met 358-Ser 359 forming an A1PI-protease complex.This complex is rapidly removed from the blood circulation. One of theendogenous roles of A1PI is to regulate the activity of neutrophilelastase, which breaks down foreign proteins and injures native tissuepresent in the lung. In the absence of sufficient quantities of A1PI,the elastase breaks down lung tissue, which over time results in chroniclung tissue damage and emphysema.

A1PI is often purified from blood plasma. See, e.g., U.S. Pat. Nos.6,284,874; 6,462,180; 6,093,804; 7,879,800; and WO 1998/000154; WO2002/048176; WO 2010/009388, for example. In addition, recombinant A1PI(recA1PI) can be expressed and purified from a variety of sources. See,e.g., U.S. Pat. Nos. 4,931,373 and 5,134,119; U.S. Patent ApplicationPublications Nos. US 2004/0124143 and US 2007/0218535; PCT PublicationNos. WO 2005/047323 and WO 2010/127939; and Archibald et al., Proc.Natl. Acad. Sci. USA 87:5178-5182 (1990); Wright et al., Nat.Biotechnology 9:830 (1991).

Methods for expressing and purifying human recombinant, cell culturederived A1PI for therapeutic use are described herein. Followingpurification, the A1PI solution had a yellow or amber color that may beobjectionable to clinicians and/or patients. Methods for diminishing thecoloration are also described herein.

SUMMARY

One embodiment described herein is a method of diminishing an amount ofcolorant in a solution comprising cell culture derived alpha₁ proteinaseinhibitor (recA1PI) comprising incubating the solution comprisingrecA1PI with a reducing agent and separating the recA1PI from thecolorant.

In some aspects described herein, the reducing agent is cysteine or DTT.

In some aspects described herein, the reducing agent is cysteine.

In some aspects described herein, the reducing agent concentration isfrom about 1 mM to about 100 mM.

In some aspects described herein, the reducing agent concentration isabout 10 mM.

In some aspects described herein, the reducint agent concentration isabout 1 mM.

In some aspects described herein, the reducing incubation step iscarried out for a time of from about 1 to about 24 hours.

In some aspects described herein, the reducing incubation step iscarried out at a temperature of from about 2° C. to about 60° C.

In some aspects described herein, the reducing agent is 10 mM cysteineand the incubation is carried out overnight at about room temperature.

In some aspects described herein, the separating the recA1PI from thecolorant comprises chromatography.

In some aspects described herein, the chromatography comprises ionexchange, hydrophobic interaction, gel filtration, affinity,immunoaffinity, or combinations thereof.

In some aspects described herein, the method comprises reducing the ironconcentration.

In some aspects described herein, the iron concentration is reduced(i.e., lowered) 2- to 100-fold.

In some aspects described herein, the iron concentration is reduced(i.e., lowered) 5- to 50-fold.

In some aspects described herein, the iron concentration is 10 μM orless.

In some aspects described herein, the iron concentration is 1 μM orless.

Another embodiment described herein is a method of purifying cellculture derived human A1PI from an aqueous solution comprising recA1PI,comprising: (a) performing a viral inactivation step on a solutioncontaining recA1PI; (b) passing the virally inactivated solution throughan anion exchanger so that recA1PI binds to the anion exchanger; (c)eluting recA1PI from the anion exchange resin to obtain an anionexchange eluate containing recA1PI; (d) adding a reducing agent to theanion exchange eluate containing recA1PI to obtain a reducing solution;(e) incubating the reducing solution; (f) passing the reducing solutionthrough a hydrophobic interaction chromatography (HIC) resin so thatrecA1PI binds to the HIC resin; and (g) eluting recA1PI from the HICresin to obtain an HIC eluate that contains recA1PI.

In some aspects described herein, the viral inactivation comprises asolvent/detergent incubation.

In some aspects described herein, the solvent is added in a range of0.01% to about 0.5%.

In some aspects described herein, the detergent is added from about 0.5%to about 2.0% weight per volume of the resulting mixture.

In some aspects described herein, the solvent/detergent incubationcomprises adding about 0.5% polysorbate 20 and about 0.03% tri(n-butylphosphate) at pH of about 8 and a temperature of about 30° C.

In some aspects described herein, the anion exchanger is a quaternaryammonium resin.

In some aspects described herein, the quaternary ammonium resin isCapto™ Q.

In some aspects described herein, the reducing agent is cysteine (Cys);cysteamine; dithiothreitol (DTT); dithioerythritol (DTE); glutathione(GSH); 2-mercaptoethanol (2-ME); 2-mercaptoethylamine (2-MEA);tris(2-carboxyethyl)phosphine (TCEP); oxalic acid; formic acid; ascorbicacid; nicotinamide adenine dinucleotide (NADH); nicotinamide adeninedinucleotide phosphate (NADPH); or combinations thereof.

In some aspects described herein, the reducing agent is cysteine or DTT.

In some aspects described herein, the reducing agent is cysteine.

In some aspects described herein, the reducing agent concentration isfrom about 1 mM to 100 mM.

In some aspects described herein, the reducing agent concentration isabout 10 mM.

In some aspects described herein, the reducing agent concentration isabout 1 mM.

In some aspects described herein, the reducing incubation step iscarried out for about 1 to 24 hours.

In some aspects described herein, the reducing incubation step iscarried out from about 2° C. to 60° C.

In some aspects described herein, the reducing agent is 10 mM cysteineand the incubation is carried out overnight at about room temperature.

In some aspects described herein, the HIC resin is Octyl Sepharose™ orCapto™ Octyl.

In some aspects described herein, the method comprises reducing the ironconcentration.

In some aspects described herein, the iron concentration is reduced(i.e., lowered) 2- to 100-fold.

In some aspects described herein, the iron concentration is reduced(i.e., lowered) 5- to 50-fold.

In some aspects described herein, the iron concentration is 10 μM orless.

In some aspects described herein, the iron concentration is 1 μM orless.

Another embodiment described herein is a method of purifying cellculture derived alpha₁ proteinase inhibitor (recA1PI) comprisingincubating a solution comprising recA1PI with a reducing agent andseparating the recA1PI from the reducing agent and the reduced species.

In some aspects described herein, the reducing agent is cysteine or DTT.

In some aspects described herein, the reducing agent is cysteine.

In some aspects described herein, the reducing agent concentration isfrom about 1 mM to about 100 mM.

In some aspects described herein, the reducing agent concentration isabout 10 mM.

In some aspects described herein, the reducing agent concentration isabout 1 mM.

In some aspects described herein, the incubation step is carried out fora time of from about 1to about 24 hours.

In some aspects described herein, the incubation step is carried out ata temperature of from about 2° C. to about 60° C.

In some aspects described herein, the reducing agent is about 10 mMcysteine and the incubation is carried out overnight at roomtemperature.

In some aspects described herein, the separating the recA1PI from thereducing agent and reduced species comprises chromatography.

In some aspects described herein, the chromatography comprises ionexchange, hydrophobic interaction, gel filtration, affinity,immunoaffinity, or combinations thereof.

In some aspects described herein, the reduced species comprises iron.

In some aspects described herein, the iron concentration is reduced(i.e., lowered) 2- to 100-fold.

In some aspects described herein, the iron concentration is reduced(i.e., lowered) 5- to 50-fold.

In some aspects described herein, the iron concentration is 10 μM orless.

In some aspects described herein, the iron concentration is 1 μM orless.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 illustrates the primary sequence of human A1PI and notablemodification sites.

FIG. 2 shows a flow chart of the purification process used for purifyingrecA1PI that results in a purified recA1PI solution having a yellowcolor.

FIG. 3 shows a chromatogram of a sample of recA1PI purified byimmunoaffinity chromatography (i.e., ATT Select resin, GE HealthcareLife Sciences).

FIG. 4 shows a UV-Vis spectrum of a sample of recA1PI purified byimmunoaffinity chromatography (i.e., ATT Select resin, GE HealthcareLife Sciences).

FIG. 5 shows a chromatogram of a sample of recA1PI purified by gelfiltration (i.e., size exclusion) chromatography using Superdex™ 200prep grade resin (GE Healthcare Life Sciences).

FIG. 6 shows a UV-Vis spectrum of a sample of recA1PI purified by gelfiltration (i.e., size exclusion) chromatography using Superdex™ 200prep grade resin (GE Healthcare Life Sciences).

FIG. 7 shows a UV-Vis spectra of three samples of human recombinant,cell culture derived A1PI having a yellow color. Sample 1 contains 4 Mguanidine hydrochloride (Gdn.HCl); sample 2 contains 50 mMdithiothreitol (DTT); sample 3 contains both 4 M Gdn.HCl and 50 mM DTT.

FIG. 8 shows a chromatogram of recA1PI treated with 50 mM DTT and thenpurified by gel filtration chromatography.

FIG. 9 shows a chromatogram of recA1PI without DTT treatment and thenpurified by gel filtration chromatography.

FIG. 10 shows UV-Vis spectra of samples of recA1PI, recA1PI treated with50 mM DTT, and highly purified, plasma-derived A1PI.

FIG. 11 shows UV-Vis spectra of samples of recA1PI, recA1PI treated with50 mM DTT, and recA1PI treated with 10 mM DTT.

FIG. 12 shows a chromatogram from a gel filtration chromatography run of50 mM DTT in PBS.

FIG. 13 shows a chromatogram from a gel filtration chromatography run ofrecA1PI treated with 50 mM DTT in PBS.

FIG. 14 shows a chromatogram from a gel filtration chromatography run ofpurified plasma derived A1PI treated with 10 mM DTT.

FIG. 15 shows a chromatogram from a gel filtration chromatography columnof recA1PI treated with 10 mM cysteine.

FIG. 16 shows a flow chart of the revised recA1PI purification procedureincluding a cysteine incubation step. Note that the cysteine incubationcan be performed at other steps in the process, such as afterhydrophobic interaction chromatography or after passing through thecation exchange membrane (bold arrows).

FIG. 17 shows a chromatogram of hydrophobic interaction chromatographyon Octyl Sepharose™ with recA1PI not treated with cysteine.

FIG. 18 shows a chromatogram of hydrophobic interaction chromatographyon Octyl Sepharose™ with recA1PI following treatment with 10 mMcysteine.

FIG. 19 shows UV-Vis spectra of recA1PI, recA1PI treated with 10 mMcysteine, or highly purified plasma-derived A1PI.

DETAILED DESCRIPTION

Described herein are methods for purifying recombinant, cell culturederived alpha₁-protease inhibitor and removing a colored species thatco-purifies with the recA1PI protein.

One aspect described herein is a method of purifying recombinant, cellculture derived human A1PI from an aqueous solution containing recA1PI.

Another method described herein is a method of diminishing thecoloration of a solution of recombinant, cell culture derived A1PIcomprising incubating the recA1PI solution with a reducing agent andseparating the recA1PI from reducing agent and the colored species.

Another method described herein is a method of purifying recombinant,cell culture derived A1PI comprising incubating a recA1PI solution witha reducing agent and separating the recA1PI from the reducing agent andthe reduced species.

EXAMPLES Example 1 Cell Growth and Expression of Human Recombinant A1PISummary

The expression of recombinant human A1PI begins by culturing humanPER.C6® cells (Crucell, Leiden, Netherlands) containing a pAATopST3plasmid construct for expressing glycosylated human recA1PI. These cellsare capable of producing high yields of glycosylated recA1PI, i.e., upto 22 picograms recA1PI per cell per day (pcd). The PER.C6®/recA1PIculture was taken through a series of scale-up steps through a 10 L wavebioreactor and a 200 L bioreactor with a target working volume of 150 L.The culture supernatant containing the recA1PI was harvested 13-14 dayslater by centrifugation at 6,000 rpm in a Celeros Centrifuge (CelerosSeparations, Foxboro, Mass.) followed by filtration prior topurification.

Vial Thaw and Shake Flask Inoculum Train

The cell culture process began with the thawing of a cryovial of PER.C6®(Crucell) human cells containing a pAATopST3 plasmid construct forexpressing glycosylated human recA1PI. Descriptions of the humanrecombinant alpha₁ protease inhibitor clone, expression, and analyses ofthe expressed recombinant A1PI are described in WO 2010/127939 and U.S.patent application Ser. No. 13/138,912, which are incorporated byreference herein for such teachings. After the vial of cells was thawed,the cells were transferred to a 125-mL flat-bottom shake flask andbrought to a final volume of 15-25 mL of CDM4PERMAb™ basal media(Hyclone) for a target viable cell density of 0.5×10⁶±0.1×10⁶ cells/mL.The 125 mL shake flask (Passage #1) were incubated for 96±4 hours at 90rpm, 36.5° C., 5.0% CO₂. The cells were then transferred to a 250 mLflat-bottom shake flask with a target volume of 100 mL and a viable celldensity of 0.5×10⁶±0.1×10⁶ cells/mL. The 250 mL flat-bottom shake flask(Passage #2) was incubated for 72 to 96 hours (±4 hours) at 125 rpm,36.5° C., 5.0% CO₂. The cells were then transferred to a 500-mLflat-bottom shake flask with a target volume of 250 mL and a viable celldensity of 0.5×10⁶±0.1×10⁶ cells/mL. The 500 mL flat-bottom shake flask(Passage #3) was incubated for 72 to 96 hours (±4 hours) at 125 rpm,36.5° C., 5.0% CO₂. The cells were then transferred to a 1 L flat-bottomshake flask with a target volume of 600 mL and a viable cell density of0.5×10⁶±0.1×10⁶ cells/mL. The 1 L flat-bottom shake flask (Passage #4)was incubated for 72 to 96 hours (±4 hours) at 125 rpm, 36.5° C., 5.0%CO₂.

Wave Bioreactor Inoculum Train

The volume from the 1 L shake flask was transferred to a 10 L Cellbag®on a 20/50EH Wave™ Bioreactor (GE Healthcare Life Sciences) to achieve aworking volume of 3.0-4.0 L and a viable cell density of 0.5.3310⁶±0.1×10⁶ cells/mL. The 10 L Cellbag® was operated for 72 to 96 hours(±4 hours) at 25 rpm, 7°-rocking angle, 0.2 liters per minute (lpm) airflow rate, 36.5° C., and 3.0% CO₂. The volume from the 10 L Cellbag wastransferred to a 50 L Cellbag® on a 20/50EH Wave Bioreactor to achieve aworking volume of 22-25 L and a viable cell density of 0.5×10⁶±0.1×10⁶cells/mL. The 50 L Cellbag® was operated for 72 to 96 hours (±4 hours)at 22 rpm, 7° rocking angle, 0.3 lpm air flow rate, 36.5° C., and 3.0%CO₂.

200 L Bioreactor

The contents of the 50 L Cellbag® were transferred to the Xcellerex 200L bioreactor through a sterile Kleenpak™ connection (Xcellerex,Marlborough, Mass.). The 200 L bioreactor should contain a minimumamount (100 L) of CDM4PERMAb™ basal media (Hyclone) and be operationalat 36.5° C., 120 rpm, with a pH in the range of 7.2±0.4 prior to theaddition of inoculum. The target working volume was 150 L at a viablecell density of 0.6×10⁶ cells/mL±0.1×10⁶ cells/mL. The pH dead band (anarea of signal range where no action occurs) was 7.2±0.4 and thedissolved oxygen setpoint was 50%. The pH was maintained by addition of1 N sodium carbonate or CO₂ gas. At 96 hours (±4 hours), PerMAB™ feedmedia (Hyclone) was added as a daily bolus shot equal to 0.3% of theinitial working volume in the bioreactor; the feed media was added at aflow rate of 100-300 mL/min. The feed media was maintained at roomtemperature during the run and was covered to prevent any degradation bylight. Antifoam was added at the start of the run at 12 ppm and wasadded in small increments to maintain a foam level in the bioreactorthat was 2 inches or less. The 200 L bioreactor was harvested at 308-340hours (12.8-14.2 days).

Centrifugation and Filtration

The material from the 200 L bioreactor was transferred to the CelerosAPD-75 1 L bowl at a flow rate of 0.5 lpm with centrifugation speed of6,000 rpm (Celeros Separations, Foxboro, Mass.). The percent solidsvalue was calculated prior to transfer to determine the number of bowldischarges needed (the 1 L bowl can hold 1 kg of solids). The centrate(the clarified solution following centrifugation) was transferred to aMillipore Pilot POD holder that contains two 1.1 m² A1HC filters at 1lpm (EMD Millipore, Billerica, Mass.). Post depth-filtration, thematerial was filtered through a 0.5/0.2 μm Millipore SHC filter.

Example 2

Purification of Human Recombinant A1PI from Cell Culture Supernatant

Summary

The purification of recA1PI begins with a three-hour solvent/detergenttreatment for viral inactivation. The recA1PI was then captured andeluted from a Capto™ Q column (GE Healthcare Life Science, Piscataway,N.J.). The following day, the purification was continued on an OctylSepharose™ column. The HIC eluate was ultrafiltered and diafiltered toenable S-membrane purification that was followed by nanofiltration foradditional viral clearance. This material was buffer-exchanged into thefinal formulation buffer and the protein concentration was adjusted tomake the formulated bulk.

Viral Inactivation of Cell Culture Supernatant

The depth-filtered cell culture supernatant was weighed, the A₂₈₀ read,and aliquots taken for sampling. The temperature and pH set points forthis viral inactivation step were 28° C.±2° C. and a pH of 7.8±0.2. A100-× stock of the TNBP/polysorbate 20 was used for the treatment,prepared by mixing 0.5 kg of polysorbate 20, 0.06 kg oftri-(n-butyl)phosphate (TNBP), and water for injection (WFI) to make upa liter of the mixture. This stock was added to the cell culturesupernatant at a 100-fold dilution and the treatment carried out for 2.5hours with stirring. The final concentrations were 0.5% for thepolysorbate 20 and 0.03% for the TNBP. Following the TNBP/polysorbate 20treatment, the cell culture supernatant was filtered.

Filtration

A Cuno 120ZA Filter Disc (3M, St. Paul, Minn.) was rinsed with hot waterfor injection (HWFI) at not more than 1 L/min for at least 10-minutes.This was followed by a rinse with cold water for injection (CWFI) of notless than 2 L and finally dried at 20 psi. The TNBP/polysorbate20-treated cell culture supernatant was passed through this filter usingan air pressure not less than 20 psi and a flow, no greater than 1L/minute. Aliquots were taken for sampling and retains.

Anion Exchange Chromatography

This step serves to capture recA1PI and eliminate host cell proteins(HCPs) in the flow-through. A 30 cm inner diameter×14 cm bed heightcolumn was used (10 L bed volume). The pH of the TNBP/polysorbate20-treated cell culture supernatant was adjusted back to 7.0±0.1. Theconductivity of the solvent/detergent-treated supernatant prior tocolumn loading was measured. The amount of ambient WFI diluent wasdetermined to ensure that the conductivity was no higher than 4 mS/cmduring column loading with inline dilution.

The Unicorn program (GE Healthcare Life Sciences) was used to run theCapto™ Q column (GE Healthcare Life Science) and the inlet lines of thechromatography system were placed in the appropriate buffer tanks. ADurapore 0.3 μm in-line filter (Millipore) was changed for everychromatography run. The Capto™ Q column was pre-equilibrated with 1column volume (CV) of 0.5 M glacial acetic acid followed byequilibration with 5 CVs of 20 mM Na₂HPO₄, pH 6.0. The cell culturesupernatant was loaded onto the Capto™ Q column by in-line dilution withwater for injection (WFI). The chromatography skid was programmed toperform the loading at a conductivity not more than 4 mS/cm at a linearflow rate of 300 cm/h. The loading was followed by a brief chase withWFI. The column was washed with 8 CV of wash buffer (20 mM Na₂HPO₄, 20mM NaCl pH 6.0) prior to a 2 CV re-equilibration with 20 mM Na₂HPO₄, pH6.0. Elution was accomplished using an 8 CV gradient ending in 25 mMNa₂HPO₄, 200 mM NaCl, pH 7.0 or by a step-wise increase in NaClconcentration. The single elution peak of recA1PI was collectedbeginning at 4 CV into the gradient and collection ends with a UV-watchgate of 0.10 AU. The elution fraction was sampled for testing andretained. L-cysteine was added to the eluate pool at a concentration of10 mM and allowed to mix overnight at room temperature.

Hydrophobic Interaction Chromatography Using Octyl Sepharose™ FF

A 45 cm inner diameter×9 cm bed height column (15 L bed volume) OctylSepharose™ 4 FF hydrophobic interaction chromatography (HIC) column (GEHealthcare Life Sciences) was equilibrated with 8 CV of HICequilibration buffer (25 mM Na₂HPO₄, 0.1 M NaCl, 1.75 M ammoniumsulfate, pH 7.0). The Capto Q eluate containing A1PI and cysteine wasloaded by inline dilution with the octyl dilution buffer (25 mM Na₂HPO₄,0.1 M NaCl, 3 M (NH₄)₂SO₄, pH 7.0) at a flow rate of 150 cm/h to achievea final concentration of 1.75 M (NH₄)₂SO₄ in the loading material.Following loading, the column was washed with 5 CV of the HICequilibration buffer. Elution was accomplished with a reverse saltgradient from the 1.75 M ammonium sulfate in the wash buffer to theelution buffer (20 mM Na₂HPO₄, pH 6.0) over 10 CV. UV absorbance watchcommands of 0.05 AU on the front and 0.10 Au on the tail were used tocollect the eluate pool.

Ultrafiltration and Diafiltration of the HIC Eluate

Three 30 kDa molecular weight cut off (MWCO) 0.1 m² membranes wereflushed with WFI at 40-50° C. until the pH of the permeate and retentatewere between 5 and 7. The feed pressure was set to a target of 25 (e.g.,a range of 24 to 28) psig while the outlet pressure was set to 5 psig(e.g., a range of 4 to 8 psig). The system was equilibrated with 1-2 Lof the HIC elution buffer for not less than 10 minutes. The HIC eluatewas mixed and the temperature maintained at 15-25° C. The permeatevolume was monitored and the UF was stopped when the concentration hasreached an A₂₈₀ target of 30. Following the reduction in the volume ofthe feed, diafiltration was performed with 6 diavolumes (DV) of thecation equilibration buffer (10 mM sodium citrate, pH 5.4). The A₂₈₀ ofthe retentate was checked to ensure that it was ≦30 and the retentatewas drained into a clean vessel. Two 1-L volumes of cation equilibrationbuffer were each recirculated with a feed pressure of 10-15 psig for notless than 5 minutes. The rinses were combined with the retentate.

Cation Exchange Chromatography Using an S Membrane

A Sartobind® S-membrane single use capsule (Sartorius, Gottingen,Germany) with a membrane surface area of 2500 cm² was equilibrated withthe cation equilibration buffer (10 mM sodium citrate dihydrate, pH 5.4)ensuring that the conductivity of the effluent was not more than 4mS/cm. The UF/DF-treated HIC eluate was loaded onto the S-membrane at 25L/h using a peristaltic pump and subsequently washed with cationequilibration buffer until the A₂₈₀ was not more than 0.1 AU. Theflow-through was collected and adjusted to pH 7.0±0.1.

Nanofiltration

Nanofiltration was performed using Viresolve® NFP (0.085 m²; Millipore)with the Viresolve® PreFilter (0.11 m²). Filtration was by constantpressure with a pressure can at not more than 50 psi. The nanofilter wasrinsed with four 500 mL volumes of cation equilibration buffer.

Final Ultrafiltration/Diafiltration

A 10 kDa MWCO membrane with a 0.3 m² membrane area was used in thisstep. The holder and membrane were flushed with WFI at 40-50° C. untilthe pH of the permeate and retentate was between 5 and 7. The feedpressure was set to a target of 25 psig (range of 24 to 28 psi) whilethe outlet pressure was set to 5 psig (range of 4 to 8 psi). The systemwas equilibrated with 1-2 L of 20 mM Na₂HPO₄, pH 7.0 for not less than10 minutes. The nanofiltrate was mixed well and the temperaturemaintained at 15-25° C. The permeate was checked periodically for lossof recA1PI by measuring its absorbance at 280 nm (i.e., A₂₈₀) whichshould be <0.04. If this value was exceeded, the UF/DF was stopped. Thepermeate volume was monitored and the UF was stopped when theconcentration has reached an A₂₈₀ target of ˜30. Following the reductionin the volume of the feed, diafiltration was performed with 5 DV of thediafiltration buffer (20 mM Na₂HPO₄, 120 mM NaCl, pH 7.0). The A₂₈₀ ofthe retentate was checked to ensure that it was ≦30 and the retentatewas drained into a clean vessel. The amount of diafiltration bufferrinse was calculated which, when added to the retentate, will result ina final concentration of 50-56 mg/mL. This rinse volume was divided inhalf and each volume was recirculated with a feed pressure of not morethan 20 psig for 3-5 minutes. The rinses were combined with theretentate.

Storage

The concentrated bulk recombinant A1PI was sterile filtered with Flexel®bags (Sartorius) and stored at −70° C., prior to final filling.

The recA1PI produced by the method described above was found to have amarked yellow color. The identity of the yellow species was unknown.Although the recA1PI was highly pure and active, removal of the yellowcolorant was desired for aesthetic reasons.

Example 3

Immunoaffinity Chromatography with Alpha-1 Antitrypsin Select Resin

An A1PI-specific immunoaffinity column was performed to determinewhether the yellow species could be separated from the purified recA1PI.A 1.6 cm inner diameter×10 cm bed height column (20 mL column volume) ofAlpha-1 Antitrypsin Select resin (AAT-Select; GE Healthcare LifeScience), specific for the plasma-derived H1PI was packed. The columnwas equilibrated with 20 mM Tris.HCl, pH 7.4. Approximately 200 mg ofrecA1PI at 10 mg/mL was loaded onto this column at 5 mL/minute. Thecolumn was washed with 20 mM Tris.HCl, pH 7.4, 100 mM NaCl and elutedwith 20 mM Tris.HCl, pH 7.4, 2 M NaCl (see FIG. 3). Fractions werecollected based on peak fractionation. The fractions under the elutionpeak were pooled and concentrated using Amicon UltraCel™ 30 kDa MWCOconcentrators (EMD Millipore, Billerica, Mass.). A UV-Vis spectrum wasacquired from the concentrated sample.

The eluate, following concentration, was distinctly yellow in color.When analyzed by UV-Vis spectroscopy (see FIG. 4), the spectrum was verysimilar to that seen for recA1PI prior to running the immunoaffinitycolumn. The conclusion from this result was that immuno-affinitychromatography was ineffective at separating the yellow color fromrecA1PI.

Example 4

Gel Filtration Chromatography with Superdex™ Resin

A gel filtration experiment (aka size exclusion chromatography; SEC) wasalso attempted to remove the yellow species from recA1PI. A 1.6 cm innerdiameter×90 cm column (bed volume of 181 mL) of Superdex™ 200 prep graderesin was packed (GE Healthcare Life Sciences). The column wasequilibrated with phosphate buffered saline (PBS; 12 mM phosphates, pH7.4, 137 mM NaCl, 2.7 mM KCl), recA1PI was loaded at 5% of the columnvolume (9 mL) and run at 2 mL/minutes (60 cm/h). Fractions of 12 mLvolume were collected for analysis.

The chromatogram for this column is shown in FIG. 5. Although, the loadis 99% recA1PI, a split peak was observed, possibly owing to saturationof the UV detector. The fractions under this peak were analyzed byUV-Vis spectrophotometry (FIG. 6). The recA1P fractions were visiblyyellow and the UV-Vis spectra of these fractions were similar to that ofthe loading material. Accordingly, the gel filtration column did notremove the yellow color from recA1PI.

Example 5 Denaturant and Reducing Agent Analyses

Because immunoaffinity and gel filtration chromatography were notsuccessful in removing the yellow color from recA1PI the use ofdenaturants and/or reducing agents were sought as potential means forremoving or diminishing the yellow color.

Approximately 1 mL of the recA1PI was mixed with 8 M guanidinehydrochloride or 500 mM DTT to achieve final concentrations of 4 Mguanidine hydrochloride or 50 mM DTT, respectively. A third sample wasmixed with both reagents. The samples were incubated at 50° C. forapproximately 2 h and individually passed through PD-10 desaltingcolumns (GE Healthcare Life Sciences). The flow-through from thesecolumns was collected by centrifugation at 1,000×g for 5 minutes.

Guanidine hydrochloride did not help with diminution and this wasreflected in the UV-Vis spectrum of this sample (FIG. 7). The 50 mM DTTtreated sample was lighter yellow compared with the guanidinehydrochloride treated sample. This sample did not have the spectralsignature at 405 nm that was characteristically observed for the recA1PI(FIG. 7). The sample treated with the combination of guanidine and DTTwas nearly colorless and missing in the spectral features in the 300-400nm range. The fact that both the guanidine hydrochloride and the DTTwere required to diminish the yellow color may indicate that the yellowcolored species is covalently bound to recA1PI.

Example 6 Reduction and Gel Filtration Chromatography

Additional experiments were performed to follow-up on the DTT reductionand gel filtration chromatography done with the PD-10 columns. The goalhere was to use a longer column to achieve better resolution of theDTT-treated sample and to process a larger quantity of reduced recA1PIfor analysis.

A 1.6 cm inner diameter×90 cm bed height (181 ml column volume) columnof Superdex™ 200 prep grade resin was prepared (GE Healthcare LifeSciences). This column was pre-equilibrated with PBS containing 5 mMDTT. A sample of recA1PI in a volume of 9 mL was treated with DTT at aconcentration of 50 mM at ambient temperature, overnight. This samplewas loaded on the column; the load constituted 5% of the column volumeand the column was run at 2 mL/minute (60 cm/h). Constant-volumefractions of 14.5 mL were collected for analysis. Appropriate fractionswere pooled and concentrated back to approximately 50 mg/mL using AmiconUltraCel™ 30 kDa MWCO spin concentrators (Millipore). A control samplethat was not treated with DTT was also run under identical conditions.

The chromatogram for the 50 mM DTT treated sample is shown in FIG. 8 andthe control sample is shown in FIG. 9. There is a distinct smaller,second peak that was seen in the SEC run with the DDT-treated sample.Fractions B1-B3, containing the recA1PI were pooled and concentrated toapproximately 50 mg/mL using a 30 kDa MWCO spin concentrator. Theconcentrated sample was analyzed by UV-Vis spectrophotometry. The UV-Visspectra shown in FIG. 10, reveals that the characteristic signature ofthe yellow starting material, recA1PI, is significantly diminished inthe concentrate from the reduced, gel filtration eluate. Highlypurified, plasma-derived human A1PI was used as a control.

Example 7 DTT Concentration Analysis

The effects of lower concentrations of DTT were analyzed by incubatingrecA1PI with DTT, purifying the sample using gel filtrationchromatography, and then obtaining the UV-Vis spectra of theconcentrated purified samples. A 1.6 cm inner diameter×90 cm bed height(181 mL column volume) column of Superdex™ 200 prep grade resin was used(GE Healthcare Life Sciences). This column was pre-equilibrated with PBScontaining 5 mM DTT. The recA1PI in a volume of 9 mL was treated withDTT at the appropriate concentration at ambient temperature, overnight.The load constituted 5% of the column volume and the column was run at 2mL/minute (60 cm/h). Constant volume fractions of 14.5 mL werecollected. Appropriate fractions were pooled and concentrated back toapproximately 50 mg/mL using 30 kDa MWCO spin concentrators.

The UV-Vis spectra of the samples treated with 10 mM DTT and 50 mM DTTshows that the 10 mM DTT concentration is as effective as 50 mM DTT fordiminishing the characteristic spectral signature of the yellow coloredrecA1PI (FIG. 11).

Example 8

Bioanalytical Analysis on DTT-treated, Gel Filtration-Purified recA1PI

MALDI TOF Analysis

Matrix-assisted laser desorption/ionization time of flight massspectrometry experiments were performed on recA1PI. The expectation wasthat the small peaks generated by DTT treatment having a yellow colormight contain a species identifiable by mass spectrometry. However,nothing was identified in these samples. Matrix effects may haveinterfered with the ionization of molecules in the 100-10,000 Da range.

Iron Concentration

Iron ions were suspected as a possible source of the yellow color. Ironis an essential transition metal in cell culture and is added to theupstream cell culture media as ferric ammonium citrate,Fe_(x)(NH₄)_(y)C₆H₅O₇. Iron analyses showed that a ˜30-fold reduction iniron content of the pooled fractions of DTT-reduced recA1PI from the gelfiltration column compared to the starting material that had 66 μM ofiron. See FIG. 13. The yellow species indicated by the arrow on thechromatogram had ˜50% of the iron from the loaded amount.

Activity Analysis

Other than the main peak fractions, none of the smaller peak fractionshad recA1PI activity.

Example 9 DTT Gel Filtration Analysis

A chromatography run was completed with DTT alone in the absence ofrecA1PI to see the chromatographic profile of DTT in the absence ofrecA1PI. A single peak was observed with an elution volume of 201 mL(FIG. 12) which corresponds to the last peak, of identical elutionvolume, seen in the test run with recA1PI sample. The fraction with aslightly yellow color corresponding to the peak indicated by the arrowin FIG. 13 is unique to the DTT-treated recA1PI samples and is absent inthe control run with only DTT.

Example 10

Treatment of Purified Plasma-Derived A1PI with 10 mM DTT

A plasma-derived A1PI product that has a yellow appearance was tested todetermine if treatment with reducing agent would also result in asimilar reduction in the yellow color. A 10 mL aliquot of plasma-derivedA1PI at approximately 50 mg/mL was treated with DTT at a finalconcentration of 10 mM. Gel filtration chromatography on Superdex™ 200prep grade resin was performed as described herein (GE Healthcare LifeSciences). The chromatogram from the run with the DTT-treatedplasma-derived A1PI is shown in FIG. 14.

The fractions corresponding to recA1PI under the main peak were pooledand concentrated to 50 mg/mL. The color of the sample was no differentfrom that of the untreated sample. This indicated that the source ofyellow color of cell culture-derived recA1PI was different from that ofthe plasma-derived A1PI.

Example 11 Analysis of Cysteine as a Reducing Agent

Cysteine was examined as an alternative reducing agent because cysteineis inexpensive and readily available. In addition, as an amino acid,cysteine is an acceptable excipient. An experiment was completed wherean aliquot of recA1PI was treated with 10 mM cysteine and processed overa gel filtration column. The chromatogram for the run is shown in FIG.15. The fractions corresponding to recA1PI were pooled and concentratedto 50 mg/mL. Cysteine was also acceptable as reducing agent.

Example 12 Color Analysis

A comparison of the color of samples treated with either DTT or cysteineat 10 mM concentration shows a substantial reduction in yellow color, atcomparable protein concentration (˜50 mg/mL). The A₂₈₀/A₄₀₅ ratio wasfollowed as an indication of yellowness of a sample, the rationale beingthat the absorbance of a solution at 405 nm is a quantitative measure ofyellow color. A higher A₂₈₀/A₄₀₅ ratio corresponds to a lighter yellowcolor of the sample. The significant yellow color of the untreatedsample is largely removed by the treatment with either DTT or cysteine.However, the yellow color removal was not complete and a tinge of yellowremains in the treated samples. The A₂₈₀/A₄₀₅ ratio tracks this trendwell and a 3-fold reduction is typically seen following treatment withreducing agents. Highly purified plasma-derived A1PI is practicallyclear with an A₂₈₀/A₄₀₅ ratio of 428.

Recombinant Cell Culture Derived A1PI Activity Recovery

The recA1PI activity recovery from experiments with size exclusionchromatography and treatment with reducing agents ranged from 80-100%(see Table 1).

TABLE 1 Recombinant cell culture derived A1PI activity recovery fromsize exclusion chromatography following treatment with DTT or cysteineSample A₂₈₀/A₄₀₅ Activity Recovery recA1PI # 4 64 100%  recA1PI # 4 + 50mM DTT 281 78% recA1PI # 6 66 100%  recA1PI # 6 + 50 mM DTT 186 108%*recA1PI # 6 + 10 mM DTT 194 87% recA1PI # 6 + 10 mM cysteine 171 90%*The measured activity of >100% was due to assay-to-assay variabilityand was interpreted to mean that there was no loss of activity.

Iron Content

The iron concentration of the treated samples was considerably reducedafter treatment with reducing agents and chromatographic purification.Reduced and purified samples were analyzed using inductively coupledplasma atomic absorption spectroscopy (ICP-AA). The extent of ionconcentration reduction ranged from approximately 14-fold for thecysteine treated sample to 27-fold for the 10 mM DTT-treated sample(Table 2) when compared to the untreated samples.

TABLE 2 Iron concentration of A1PI samples from size exclusionchromatography following treatment with DTT or cysteine Sample IronConcentration (μM) recA1PI # 4 66.4 recA1PI # 4 + 50 mM DTT 3.0 recA1PI# 6 12.6 recA1PI # 6 + 10 mM DTT 0.5 recA1PI # 6 + 10 mM cysteine 0.8

Example 13 Revised A1PI Purification Procedure: Reducing Agent Additionand Incubation Following Anion Exchange Chromatography

FIG. 16 shows a flow chart of the revised recA1PI purificationprocedure, where cysteine is added to the pooled anion exchange eluate.The revised procedure follows. After the solvent/detergent viralinactivation step, cell culture supernatant, having a mass 11.2 kg, waspurified on a 5 cm inner diameter×25 cm bed height (500 mL) Capto™ Qcolumn (GE Healthcare Life Sciences) at 300 cm/h. The column wasequilibrated in 20 mM Na₂HPO₄, pH 6.0; washed with 20 mM Na₂HPO₄, 20 mMNaCl, pH 6.0; and eluted with 25 mM Na₂HPO₄, 200 mM NaCl, pH 7.0, over 8CV. The A₂₈₀ of the Q-eluate was 2.4, corresponding to an approximatepotency of 2 g/L. A 500 mL aliquot of this Q-eluate containingapproximately 1 g of recA1PI by activity was treated with 10 mM cysteine(Acros Chemicals; Thermo Fisher Scientific; New Jersey) and incubated atroom temperature overnight (˜25° C. ca. 16 h). The treated sample wasdiluted 42:58 with HIC dilution buffer, 25 mM Na₂HPO₄, 100 mM NaCl, 3 M(NH₄)₂SO₄, pH 7.0, and used to load an Octyl Sepharose™ column ofdimensions, 5 cm inner diameter×10.3 cm bed height (202 mL bed volume).The column was equilibrated with 25 mM Na₂HPO₄, 100 mM NaCl, 1.75 M(NH₄)₂SO₄, pH 7.0, and eluted with a gradient of 20 mM Na₂HPO₄, pH 6.0,over 10 CV. The eluate volume of 620 mL, was concentrated to 50 mL usinga LabScale™ TFF system and a Pellicon® 30 kDa, 3×50 cm² filter(Millipore). The sample was further concentrated to 50 mg/mL usingAmicon UltraCel™ 30 kDa MWCO concentrators (Millipore) by centrifugationat 3,500 rpm at 4° C. The concentrated sample was then passed over aSartobind® S-membrane capsule (Sartorius, Gottingen, Germany)equilibrated in 10 mM sodium citrate buffer, pH 5.4. This sample wasdiafiltered against 5-column volumes of PBS.

A control run was also performed using an identical volume of Q-eluateand processed over the HIC column in an identical manner, in the absenceof cysteine. The HIC chromatography profiles of the control andcysteine-treated test samples were comparable (cf. FIG. 17 and FIG. 18).This indicated that the addition of cysteine did not change thepurification profile of recA1PI over the hydrophobic interaction column.When the samples were concentrated to approximately 50 mg/mL, asubstantial reduction in the yellow color was observed that correspondedto a 3.4-fold improvement in the A₂₈₀/A₄₀₅ ratio (i.e., 73 vs. 245). TheUV-Vis spectra also reflect this difference, with the profile of thecysteine-treated sample being comparable to that of highly purifiedplasma-derived A1PI; see FIG. 10.

Accordingly, the overnight cysteine incubation between the anionexchange column and hydrophobic interaction chromatography (see FIG. 16)in preparative-scale runs produces comparable results to those ofbench-scale experiments in terms of yellow color clearance and acorresponding improvement in the A₂₈₀/A₄₀₅ ratio.

The scope of the devices and methods described herein includes allcombinations of embodiments, aspects, examples, steps, and preferencesherein described.

What is claimed is:
 1. A method of diminishing an amount of colorant ina solution comprising cell culture derived alpha₁ proteinase inhibitor(recA1PI) comprising incubating the solution comprising recA1PI with areducing agent and separating the recA1PI from the colorant.
 2. Themethod of claim 1, wherein the reducing agent is cysteine or DTT.
 3. Themethod of claim 1, wherein the reducing agent is cysteine.
 4. The methodof claim 1, wherein the reducing agent concentration is from about 1 mMto about 100 mM.
 5. The method of claim 1, wherein the reducing agentconcentration is about 10 mM.
 6. The method of claim 1, wherein thereducing agent concentration is about 1 mM.
 7. The method of claim 1,wherein the reducing incubation step is carried out for a time of fromabout 1 to about 24 hours.
 8. The method of claim 1, wherein thereducing incubation step is carried out at a temperature of from about2° C. to about 60° C.
 9. The method of claim 1, wherein the reducingagent is 10 mM cysteine and the incubation is carried out overnight atabout room temperature.
 10. The method of claim 1, wherein theseparating the recA1PI from the colorant comprises chromatography. 11.The method of claim 10 wherein the chromatography comprises ionexchange, hydrophobic interaction, gel filtration, affinity,immunoaffinity, or combinations thereof.
 12. The method of claim 1,comprising reducing the iron concentration.
 13. The method of claim 12,wherein the iron concentration is reduced (i.e., lowered) 2- to100-fold.
 14. The method of claim 12, wherein the iron concentration isreduced (i.e., lowered) 5- to 50-fold.
 15. The method of claim 12,wherein the iron concentration is 10 μM or less.
 16. The method of claim12, wherein the iron concentration is 1 μM or less.
 17. A method ofpurifying cell culture derived human A1PI from an aqueous solutioncomprising recA1PI, comprising: (a) performing a viral inactivation stepon a solution containing recA1PI; (b) passing the virally inactivatedsolution through an anion exchanger so that recA1PI binds to rise anionexchanger; (c) eluting recA1PI from the anion exchange resin to obtainan anion exchange eluate containing recA1PI; (d) adding a reducing agentto the anion exchange eluate containing recA1PI to obtain a reducingsolution; (e) incubating the reducing solution; (f) passing the reducingsolution through a hydrophobic interaction chromatography (HIC) resin sothat recA1PI binds to the HIC resin; and (g) eluting recA1PI from theHIC resin to obtain an HIC eluate that contains recA1PI.
 18. The methodof claim 17, wherein the viral inactivation comprises asolvent/detergent incubation.
 19. The method of claim 18, wherein thesolvent is added in a range of 0.01% to about 0.5%.
 20. The method ofclaim 18, wherein the detergent is added from about 0.5% to about 2.0%weight per volume of the resulting mixture.
 21. The method of claim 18,wherein the solvent/detergent incubation comprises adding about 0.5%polysorbate 20 and about 0.03% tri(n-butyl phosphate) at pH of about 8and a temperature of about 30° C.
 22. The method of claim 17, whereinthe anion exchanger is a quaternary ammonium resin.
 23. The method ofclaim 22, wherein the quaternary ammonium resin is Capto™ Q.
 24. Themethod of claim 17, wherein the reducing agent is cysteine (Cys);cysteamine; dithiothreitol (DTT); dithioerythritol (DTE); glutathione(GSH); 2-mercaptoethanol (2-ME); 2-mercaptoethylamine (2-MEA);tris(2-carboxyethyl)phosphine (TCEP); oxalic acid; formic acid; ascorbicacid; nicotinamide adenine dinucleotide (NADH); nicotinamide adeninedinucleotide phosphate (NADPH); or combinations thereof.
 25. The methodof claim 17, wherein the reducing agent is cysteine or DTT.
 26. Themethod of claim 17, wherein the reducing agent is cysteine.
 27. Themethod of claim 17, wherein the reducing agent concentration is fromabout 1 mM to 100 mM.
 28. The method of claim 17, wherein the reducingagent concentration is about 10 mM.
 29. The method of claim 17, whereinthe reducing agent concentration is about 1 mM. 30 The method of claim17, wherein the reducing incubation step is carried out for about 1 to24 hours.
 31. The method of claim 17, wherein the reducing incubationstep is carried out from about 2° C. to 60° C.
 32. The method of claim17, wherein the reducing agent is 10 mM cysteine and the incubation iscarried out overnight as about room temperature.
 33. The method of claim17, wherein the HIC resin is Octyl Sepharose™ or Capto™ Octyl.
 34. Themethod of claim 17, comprising reducing the iron concentration.
 35. Themethod of claim 34, wherein the iron concentration is reduced (i.e.,lowered) 2- to 100-fold.
 36. The method of claim 34, wherein the ironconcentration is reduced (i.e., lowered) 5- to 50-fold.
 37. The methodof claim 34, wherein the iron concentration is 10 μM or less.
 38. Themethod of claim 34, wherein the iron concentration is 1 μM or less. 39.A method of purifying cell culture derived alpha₁ proteinase inhibitor(recA1PI) comprising incubating a solution comprising recA1PI with areducing agent and separating the recA1PI from the reducing agent andthe reduced species.
 40. The method of claim 39, wherein the reducingagent is cysteine or DTT.
 41. The method of claim 39, wherein thereducing agent is cysteine.
 42. The method of claim 39, wherein thereducing agent concentration is from about 1 mM to about 100 mM.
 43. Themethod of claim 39, wherein the reducing agent concentration is about 10mM.
 44. The method of claim 39, wherein the reducing agent concentrationis about 1 mM.
 45. The method of claim 39, wherein the incubation stepis carried out for a time of from about 1 to about 24 hours.
 46. Themethod of claim 39, wherein the incubation step is carried out at atemperature of from about 2° C. to about 60° C.
 47. The method of claim39, wherein the reducing agent is about 10 mM cysteine and theincubation is carried out overnight at about room temperature.
 48. Themethod of claim 39, wherein the separating the recA1PI from the reducingagent and reduced species comprises chromatography.
 49. The method ofclaim 48, wherein the chromatography comprises ion exchange, hydrophobicinteraction, gel filtration, affinity, immunoaffinity, or combinationsthereof.
 50. The method of claim 39 wherein the reduced speciescomprises iron.
 51. The method of claim 50, wherein the ironconcentration is reduced (i.e., lowered) 2- to 100-fold.
 52. The methodof claim 50, wherein the iron concentration is reduced (i.e., lowered)5- to 50-fold.
 53. The method of claim 50, wherein the ironconcentration is 10 μM or less.
 54. The method of claim 50, wherein theiron concentration is 1 μM or less.